Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains

Scandinavian Journal of Infectious Diseases

Volumn 42, Issue 6-7, 2010, Pages 506-509

  Hebert, Courtney ^a   Villaran, Ralph ^a   Tolentino, Jocelyn ^a   Best, Leyla ^b   Boonlayangoor, Sue ^a   Pitrak, David ^a   Lin, Michael ^c   Weber, Stephen G ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b Department of Medicine   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; FLUCONAZOLE; PIPERACILLIN PLUS TAZOBACTAM; ANTIFUNGAL AGENT; PENICILLANIC ACID; PIPERACILLIN;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA; CANDIDEMIA; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EXPOSURE; FUNGAL STRAIN; HOSPITAL INFECTION; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RISK FACTOR; ANALOGS AND DERIVATIVES; ANTIFUNGAL RESISTANCE; CANDIDIASIS; DRUG EFFECTS; FUNGEMIA; RISK; STATISTICAL MODEL;

ADULT; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CIPROFLOXACIN; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGEMIA; HUMANS; LOGISTIC MODELS; ODDS RATIO; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77953247420     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365541003699631     Document Type: Article

References (11)

1. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fl uconazole use. J Hosp Infect 2002;50:56-65.
2. Lee I, Fishman NO, Zaoutis TE, et al. Risk factors for fl uconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med 2009;169:379-383
3. Lin MY, Carmeli Y, Zumsteg J, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case - case - control study. Antimicrob Agents Chemother 2005;49:4555-4560
4. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004;10:1125-1128
5. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fl uconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006;19:435-447
6. Carmeli Y, Eliopoulos GM, Samore MH. Antecedent treatment with different antibiotic agents as a risk factor for vancomycinresistant Enterococcus. Emerg Infect Dis 2002;8:802-807
7. Pultz NJ, Stiefel U, Ghannoum M, Helfand MS, Donskey CJ. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob Agents Chemother 2005;49: 438-440
8. Samonis G, Gikas A, Anaissie EJ, et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother 1993;37:51-53
9. Brismar B, Edlund C, Malmborg AS, Nord CE. Ciprofl oxacin concentrations and impact of the colon microfl ora in patients undergoing colorectal surgery. Antimicrob Agents Chemother 1990;34:481-483
10. Edlund C, Nord CE. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microfl ora. Infection 1988;16:8-12.
11. Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fl uconazole prophylaxis: systematic review. J Infect 2007;54:521-529